STOCKHOLDERS’ EQUITY

Accumulated Other Comprehensive Income

The changes in accumulated other comprehensive income are included in the table below.



	Three Months Ended March 31, 2018
(in thousands)	Unrealized Gains and Losses on Short-term Investments			Foreign Currency Items		Total
Beginning balance	$	(23	)	$	122	$	99
Other comprehensive income before reclassifications	5			—		5
Amounts reclassified from accumulated other comprehensive income	—			—		—
Net current period other comprehensive income	5			—		5
Ending Balance	$	(18	)	$	122	$	104

Stock Repurchase Program

On November 1, 2007, the Company announced its Board of Directors (the "Board")’ authorized the repurchase of up to $50.0 million of the Company’s common stock (“Stock Repurchase Program”). In addition, on October 22, 2014, the Board authorized another $30.0 million under the share repurchase program. The Company may repurchase its common stock for cash in the open market in accordance with applicable securities laws. The timing and amount of any stock repurchase will depend on share price, corporate and regulatory requirements, economic and market conditions, and other factors. The stock repurchase authorization has no expiration date, does not require the Company to repurchase a specific number of shares, and may be modified, suspended, or discontinued at any time.

There were no stock repurchase during the three months ended March 31, 2018 and 2017. As of March 31, 2018, the Stock Repurchase Program remains available with approximately $33.4 million that may yet be purchased under the program.

Stockholders Right Plan

On December 26, 2017, the Board declared a dividend of one right (a “Right”) for each of the Company's issued and outstanding shares of common stock, par value $0.001 per share. The dividend was paid to the stockholders of record at the close of business on January 8, 2018 (the “Record Date”). Each Right entitles the holder to purchase from the Company one one-thousandth of a share of the Company’s Series B Junior Participating Preferred Stock (the “Preferred Stock”) at a price of $30.00(the “Exercise Price”), subject to certain adjustments and contingently issuable.

There were no rights exercised during the three months ended March 31, 2018 and 2017.